Acute myeloid leukemia (AML) is a fast-growing cancer of the bone marrow, the soft tissue inside bones where blood cells are made. In AML, very early “baby” myeloid cells (called blasts) start to grow out of control. These blasts do not mature into healthy white cells, red cells, or platelets. Because the bad cells multiply quickly, they crowd out normal cells. This causes anemia (low red cells), infection risk (low healthy white cells), and bleeding or bruising (low platelets). AML can spread from the marrow into the blood and then to the spleen, liver, skin, gums, or the brain and spinal fluid. It is a medical emergency when the white cell count becomes very high (leukostasis) or when serious infections or bleeding appear. Diagnosis is made by blood tests and bone marrow examination, confirmed by special markers on the cells and by chromosome and gene testing. Treatment needs to start quickly and usually has two parts: “induction” to force the leukemia into remission, and “consolidation” (more chemotherapy, targeted pills, or a stem-cell transplant) to keep it away. Outcomes depend on age, overall health, and the leukemia’s genetic features. Some subtypes, such as acute promyelocytic leukemia (APL), have unique treatment and urgent bleeding risks but can be highly curable with the right medicines.
Acute myeloid leukemia (AML) is a fast-growing cancer of the blood and bone marrow. In AML, young white blood cells (called myeloid blasts) do not mature. They multiply quickly and fill the bone marrow. Because of this, the body cannot make enough healthy red cells, platelets, and infection-fighting white cells. People feel tired, bruise or bleed easily, and get infections. AML is an emergency because it grows fast, but many treatments exist. Care usually includes strong anti-cancer drugs, targeted pills for special gene changes, and sometimes a stem cell transplant. Good supportive care for infection, bleeding, and side effects is also very important.
Other names
AML is also called acute myelogenous leukemia, acute myelocytic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia (ANLL)—older terms that mean the same thing. When it forms a solid tumor outside the marrow it may be called myeloid sarcoma or chloroma. Subtypes include acute promyelocytic leukemia (APL), acute myelomonocytic leukemia, and acute monocytic leukemia. Modern reports also label cases by key mutations, such as NPM1-mutated AML or CEBPA-mutated AML.
Types of AML
Doctors classify AML in several helpful ways. You may see one or more of these systems used together:
-
By clinical setting
-
De novo AML: AML appears without a known earlier blood disorder or treatment exposure.
-
Therapy-related AML (t-AML): AML that develops after prior chemotherapy or radiation for another cancer.
-
AML with myelodysplasia-related features (AML-MR): AML evolving from a long-standing bone marrow problem (like MDS) or showing typical MDS-type genetic changes.
-
By cell appearance and behavior (classic FAB M0–M7 subtypes)
These older “FAB” labels are still widely used to describe how the blasts look and what they do:
-
M0: Minimally differentiated AML—very early myeloid blasts.
-
M1: AML without maturation—blasts dominate, few maturing cells.
-
M2: AML with maturation—blasts plus some maturing neutrophils.
-
M3 (APL): Acute promyelocytic leukemia—promyelocytes, high bleeding risk; special treatment (ATRA/arsenic).
-
M4: Acute myelomonocytic leukemia—both neutrophil and monocyte features.
-
M4Eo: M4 with increased eosinophils—often tied to a specific chromosome change.
-
M5: Acute monocytic/monoblastic leukemia—gum swelling and skin involvement can be prominent.
-
M6: Acute erythroid leukemia—abnormal red-cell precursors dominate.
-
M7: Acute megakaryoblastic leukemia—platelet-line blasts; sometimes linked with Down syndrome.
-
By chromosome and gene changes (genomic subtypes)
Modern care strongly depends on genetics. Important groups include:
-
Core-binding factor AML (e.g., t(8;21) or inv(16)/t(16;16)): often better risk when treated well.
-
APL with PML::RARA fusion: a unique disease with targeted therapy.
-
NPM1-mutated AML: common adult subtype; risk depends on other mutations like FLT3.
-
CEBPA-mutated AML (biallelic/ in-frame): can be favorable risk.
-
FLT3-mutated AML (ITD or TKD): guides use of FLT3 inhibitors.
-
IDH1/IDH2-mutated AML: guides use of IDH inhibitors.
-
KMT2A-rearranged AML, RUNX1-mutated, TP53-mutated, complex karyotype: often higher risk and treated more aggressively or with transplant when possible.
Causes and risk factors
-
Older age: The chance of AML rises with age because blood-forming stem cells collect more DNA damage over time.
-
Male sex: Men have a slightly higher AML rate; the exact reasons are not fully clear but may include exposures and biology.
-
Prior chemotherapy: Drugs like alkylating agents or topoisomerase II inhibitors can injure marrow DNA, leading to therapy-related AML years later.
-
Prior radiation therapy: High-dose radiation used for earlier cancers can damage marrow stem cells and raise AML risk.
-
Long-standing myelodysplastic syndrome (MDS): MDS can slowly transform into AML as abnormal clones gain more mutations.
-
Myeloproliferative neoplasms (MPN): Conditions like polycythemia vera or myelofibrosis can “blast” and progress to AML.
-
Benzene exposure: This industrial chemical harms marrow DNA; chronic exposure increases leukemia risk.
-
Cigarette smoking: Smoke contains benzene and other carcinogens that can reach the marrow and raise AML risk.
-
Pesticides/solvents: Some occupational or environmental chemicals are linked to higher AML rates.
-
Ionizing radiation (non-medical): High-level accidental or occupational exposure can increase leukemia risk years later.
-
Clonal hematopoiesis (CHIP/CCUS): Age-related gene changes in blood cells (like DNMT3A, TET2) raise the chance of later AML.
-
Germline RUNX1 mutation (familial platelet disorder): Inherited changes cause platelet problems and higher AML risk.
-
Germline CEBPA mutation: Families with this mutation show higher rates of AML, often at a younger age.
-
Germline GATA2 deficiency: Causes immune and marrow problems; AML risk is high without transplant.
-
Germline DDX41 mutation: Often causes AML in later adulthood; sometimes multiple family members are affected.
-
Down syndrome (trisomy 21): Increases risk of certain AML forms in infants and children, especially megakaryoblastic AML.
-
Fanconi anemia: Inherited DNA-repair disease with high risk of AML due to fragile chromosomes.
-
Shwachman–Diamond syndrome: Inherited marrow failure with pancreatic problems; AML can develop over time.
-
Aplastic anemia history: Rarely, after immune therapy or long disease course, abnormal clones may evolve into AML.
-
Previous stem-cell or solid-organ transplant with long-term immune suppression: Chronic immune pressure and medicine side effects can allow abnormal clones to grow and progress to AML.
Common symptoms and signs
-
Tiredness and weakness: Low red blood cells (anemia) reduce oxygen delivery; daily tasks feel exhausting.
-
Shortness of breath on effort: With anemia, climbing stairs or walking fast becomes hard and breathless.
-
Pale skin: Less hemoglobin makes the skin and inner eyelids look pale.
-
Fever: Low normal white cells and poor immune function let infections start easily; fever may be the first clue.
-
Frequent or severe infections: Repeated sore throats, pneumonia, urinary infections, or slow-healing wounds may occur.
-
Easy bruising: Low platelets make small bumps cause big bruises.
-
Bleeding: Nosebleeds, bleeding gums, or long bleeding from cuts; in APL, dangerous internal bleeding can happen.
-
Tiny red spots (petechiae): Pin-point skin dots from capillary bleeding due to low platelets.
-
Bone or joint pain: Overcrowded marrow stretches the bone lining and causes aching.
-
Fullness in the left upper belly: Enlarged spleen from leukemia cell buildup causes discomfort or early satiety.
-
Weight loss and poor appetite: Cancer-related inflammation and early fullness reduce intake.
-
Night sweats: Systemic inflammation can cause drenching sweats during sleep.
-
Swollen gums: Especially in monocytic AML, leukemia cells invade the gums, making them thick and sore.
-
Skin changes: Painless lumps or patches (leukemia cutis) can appear where cells collect in skin.
-
Headache, confusion, or vision trouble: Very high white counts can make blood thick (leukostasis) or AML can spread to the brain and eyes; this is urgent.
Diagnostic tests
A) Physical examination
-
General exam and vital signs: The doctor checks temperature, pulse, blood pressure, and oxygen level to look for fever, infection risk, and low oxygen from anemia or lung issues.
-
Skin and mucosa check: Looking for pallor, bruises, petechiae, and gum swelling helps point toward low blood counts and monocytic involvement.
-
Spleen and liver exam: Gentle pressing under the ribs checks for enlargement (hepatosplenomegaly), which suggests leukemia cells collecting there.
-
Neurologic screening: Brief checks for headaches, confusion, weakness, or vision problems can uncover leukostasis or central nervous system spread.
B) Manual bedside tests
-
Lymph node palpation: Feeling for enlarged, firm, non-tender nodes helps document disease spread or rule out other causes like lymphoma.
-
Orthostatic blood pressure/heart rate: Standing measurements can show poor blood volume or anemia-related dizziness.
-
Bleeding time surrogates (bedside assessment of bleeding risk): While formal bleeding time is outdated, careful review of gum bleeding, nosebleeds, and skin findings helps guide urgency and transfusion needs.
-
Performance status scoring (ECOG/ Karnofsky, done manually during exam): A simple graded score of daily activity ability helps decide how intense treatment can be.
C) Laboratory and pathological tests
-
Complete blood count (CBC) with differential: Shows anemia, low platelets, and abnormal white counts; may show blasts in the blood smear.
-
Peripheral blood smear review: A pathologist looks at cell shape and maturity; Auer rods suggest myeloid blasts.
-
Bone marrow aspiration: A sample of liquid marrow is examined to count blasts (≥20% blasts usually confirms AML) and to evaluate cell lines.
-
Bone marrow core biopsy: A small solid piece of marrow shows overall architecture, fibrosis, and cellularity; it complements the aspiration.
-
Flow cytometry immunophenotyping: Tests for surface and inside markers (like CD33, CD13, MPO, CD34) to prove the cells are myeloid and to define the subtype.
-
Cytogenetics (karyotype and FISH): Looks at chromosomes for translocations (e.g., t(8;21), inv(16), t(15;17)) or complex changes that predict risk and guide therapy.
-
Molecular testing (NGS panel): Finds gene mutations such as NPM1, FLT3, IDH1/2, TP53, CEBPA, RUNX1; results tailor targeted drugs and transplant plans.
-
Basic labs for treatment readiness: Chemistry panel, uric acid, LDH, phosphorus, and kidney/liver tests assess tumor lysis risk and safe dosing before chemotherapy.
D) Electrodiagnostic tests
-
Electrocardiogram (ECG): Many AML drugs can affect the heart’s rhythm or strain it; a baseline ECG checks electrical activity and QT interval.
-
Pulse oximetry/telemetry monitoring when needed: Continuous or repeated oxygen level checks help detect breathing problems from infection, anemia, or leukostasis; monitors can track heart rate and rhythm during acute care.
E) Imaging tests
-
Chest X-ray: Quickly checks for pneumonia, fluid around the lungs, or line placement; important before intensive treatment.
-
Ultrasound or CT of abdomen (as indicated): Looks for enlarged liver/spleen, bleeding, or abscess; helps plan procedures such as central line insertion or evaluate pain.
Non-Pharmacological Treatments
(We group items into 15 Physiotherapy approaches + Mind-Body, Gene/Educational therapies. These methods support medical treatment. They do not replace chemotherapy, targeted therapy, or transplant.)
1) Graded aerobic activity (Physiotherapy)
Description: Gentle, step-by-step cardio helps fight fatigue and muscle loss during AML treatment. Start with short walks at home or on a treadmill for 5–10 minutes, 3–5 days per week. Increase time slowly if your care team allows. Use a simple talk test: you should be able to speak in short sentences. Add light cycling or slow stair practice if balance is safe. On days with low energy or low blood counts, cut duration and pace. Exercise should stop if you feel dizzy, very short of breath, chest pain, or if you have a fever or active bleeding. Wear stable shoes. Avoid public gyms when neutrophils are very low. Clean equipment before and after use. This gentle plan maintains heart fitness, supports mood, and may reduce cancer-related fatigue.
Purpose: Maintain stamina and reduce fatigue.
Mechanism: Improves oxygen use and mitochondrial function.
Benefits: Better energy, mood, sleep, and daily function.
2) Progressive resistance training with bands (Physiotherapy)
Description: Use light resistance bands 2–3 times weekly for major muscle groups (legs, back, chest, arms). Do 1–2 sets of 8–12 slow reps. Keep breathing steady. Avoid straining and avoid sessions if platelets are very low or if you have bone pain or active bleeding.
Purpose: Maintain or rebuild muscle.
Mechanism: Stimulates muscle protein synthesis.
Benefits: Stronger legs and arms, safer transfers, less fall risk.
3) Range-of-motion and gentle stretching (Physiotherapy)
Description: Daily neck, shoulder, hip, knee, and ankle movements within comfortable range, plus 10–20-second stretches without bouncing.
Purpose: Prevent stiffness from bed rest.
Mechanism: Lubricates joints and lengthens soft tissues.
Benefits: Easier dressing, turning in bed, and reaching.
4) Balance and gait training (Physiotherapy)
Description: Simple tandem stance near a counter, marching in place, and slow heel-to-toe walking with supervision.
Purpose: Reduce falls, especially if weak or dizzy.
Mechanism: Trains vestibular and proprioceptive systems.
Benefits: Safer walking, more confidence.
5) Breathing exercises and inspiratory muscle training (Physiotherapy)
Description: Diaphragmatic breathing, 5–10 minutes twice daily. Use an incentive spirometer if provided.
Purpose: Keep lungs clear during hospital stays.
Mechanism: Expands small airways and improves ventilation.
Benefits: Less atelectasis, easier cough, improved calm.
6) Energy conservation and pacing (Physiotherapy)
Description: Break tasks into chunks, sit for grooming, schedule activity after rest, and keep items within easy reach.
Purpose: Manage fatigue.
Mechanism: Matches energy supply to demand.
Benefits: More control over the day, fewer crashes.
7) Orthostatic intolerance management (Physiotherapy)
Description: Slow position changes, ankle pumps before standing, compression stockings if advised, and hydration per plan.
Purpose: Reduce dizziness on standing.
Mechanism: Improves venous return and autonomic response.
Benefits: Fewer near-falls, more comfortable mobility.
8) Peripheral neuropathy safety training (Physiotherapy)
Description: If chemo causes numb feet, use wide-base shoes, night lights, and tactile cues when stepping.
Purpose: Prevent injuries.
Mechanism: Compensates for reduced sensation.
Benefits: Fewer trips and skin injuries.
9) Lymphatic and edema self-care (Physiotherapy)
Description: Elevate limbs, ankle pumps, and gentle compression if approved.
Purpose: Control swelling from inactivity or IV fluids.
Mechanism: Supports lymph and venous flow.
Benefits: Less heaviness, better shoe fit.
10) Joint protection during thrombocytopenia (Physiotherapy)
Description: Low-impact movements, avoid high-force lifting or contact exercise when platelets are low.
Purpose: Lower bleed risk.
Mechanism: Reduces mechanical stress.
Benefits: Safer movement routine.
11) Postural training (Physiotherapy)
Description: Wall slides, scapular setting, and short posture breaks every hour.
Purpose: Ease neck/upper back pain from bed rest.
Mechanism: Rebalances muscle activation.
Benefits: Less pain, better breathing mechanics.
12) Safe transfer and gait aid training (Physiotherapy)
Description: Learn correct sit-to-stand, stair strategy, and cane/walker use if needed.
Purpose: Independence with safety.
Mechanism: Motor learning and task practice.
Benefits: Fewer falls, more confidence.
13) Gentle yoga adapted for low counts (Physiotherapy)
Description: Slow, chair-based or mat poses; avoid inversions and deep twists; stop with symptoms.
Purpose: Flexibility and calm.
Mechanism: Combines stretch with breath regulation.
Benefits: Less anxiety, improved sleep.
14) Qigong or tai chi minis (Physiotherapy)
Description: 5–10-minute standing or seated sequences.
Purpose: Balance and mind-body calm.
Mechanism: Slow rhythmic movement reduces sympathetic drive.
Benefits: Better steadiness, lower stress.
15) Pelvic floor and core activation (Physiotherapy)
Description: Gentle core bracing and pelvic floor cues in supine or seated positions.
Purpose: Support posture and continence under stress.
Mechanism: Recruits deep stabilizers.
Benefits: Less back strain, improved function.
16) Mindfulness-based stress reduction (Mind-Body)
Description (≈150 words): Short, daily mindfulness practices help manage fear, fatigue, and pain during AML care. Sit comfortably and focus on slow breaths for 5 minutes, noticing thoughts without judging them. Add a body scan once daily: move attention from toes to head, observing sensations. Pair these with brief mindful walking in a hallway or yard on good days. Use a simple audio guide if that helps. Mindfulness is safe and flexible; it fits into hospital rooms and home rest periods. It does not replace medical care, but it can lower anxiety and improve sleep quality.
Purpose: Reduce stress and improve coping.
Mechanism: Down-regulates the amygdala and sympathetic arousal.
Benefits: Calmer mood, better sleep, improved pain tolerance.
17) Guided imagery and relaxation audio (Mind-Body)
Description: Listen to calming scripts that picture safe, peaceful places and recovery pathways.
Purpose: Ease treatment anxiety and procedure distress.
Mechanism: Engages cortical networks that dampen stress response.
Benefits: Lower heart rate, less anticipatory nausea.
18) Cognitive behavioral coping skills (Mind-Body)
Description: Short sessions (with a trained therapist if available) to reframe catastrophic thoughts, plan problem-solving steps, and set small goals.
Purpose: Improve resilience during long treatments.
Mechanism: Changes thought-emotion-behavior loops.
Benefits: Less depression, clearer action plans.
19) Sleep hygiene plan (Mind-Body)
Description: Fixed wake time, dark cool room, limit naps to 20–30 minutes, no caffeine late, wind-down routine.
Purpose: Improve restorative sleep.
Mechanism: Resets circadian cues and homeostatic sleep drive.
Benefits: Better energy and mood.
20) Meaning-centered and spiritual care (Mind-Body)
Description: Short conversations about values, sources of meaning, and legacy activities (letters, recordings, photo curation).
Purpose: Support purpose and hope.
Mechanism: Aligns actions with personal values, lowers distress.
Benefits: Greater peace and engagement.
21) Genetic counseling and education (Gene/Educational)
Description : Many AML cases have gene changes in the leukemia cells (such as FLT3, NPM1, IDH1, IDH2, RUNX1). These are not inherited in most people, but they guide targeted drugs and transplant decisions. A genetic counselor and your oncology team explain which tests are done: cytogenetics (karyotype), FISH, and next-generation sequencing panels. They discuss what each result means for treatment choices and prognosis. They also explain when germline testing is considered (for example, if there is strong family history or special patterns). Education covers how targeted pills work, why drug interactions (like grapefruit with certain pills) matter, and how results affect clinical trial eligibility.
Purpose: Understand test results to pick the best therapy.
Mechanism: Knowledge improves shared decisions.
Benefits: Clearer treatment path and fewer surprises.
22) Chemotherapy class and side-effect school (Educational)
Description: Short teaching on neutropenia, fever rules, mouth care, nausea plans, and when to call.
Purpose: Early action against emergencies.
Mechanism: Recognize warning signs quickly.
Benefits: Faster care, safer recovery.
23) Infection-safe daily living training (Educational)
Description: Hand hygiene, food safety, mask use in crowds, dental care, and pet/plant handling guidance during low counts.
Purpose: Lower infection risk.
Mechanism: Reduces exposure to pathogens.
Benefits: Fewer fevers, fewer hospital days.
24) Financial, work, and caregiver planning (Educational)
Description: Social work assistance for leave paperwork, transport, housing near transplant center, and caregiver scheduling.
Purpose: Reduce life stress that blocks recovery.
Mechanism: Solves practical barriers to care.
Benefits: Better adherence, less burnout.
25) Gentle creative arts or music therapy (Mind-Body)
Description: Short, enjoyable sessions matching energy level (drawing, journaling, light instrument).
Purpose: Process emotions and improve mood.
Mechanism: Activates reward and expression networks.
Benefits: Less anxiety and isolation.
Drug Treatments
Doses are typical adult starting regimens; clinicians individualize for age, kidney/liver function, and drug interactions. Always follow your oncology team’s exact plan.
1) Cytarabine (Ara-C)
Class: Antimetabolite (pyrimidine analog).
Typical dosage/time: “7” of “7+3” induction: 100–200 mg/m²/day by continuous IV infusion on Days 1–7; high-dose Ara-C (HiDAC) 1.5–3 g/m² IV q12h on Days 1,3,5 for consolidation in fit patients.
Purpose: Core backbone of AML induction and consolidation.
Mechanism: Incorporates into DNA, blocks polymerase, triggers apoptosis in rapidly dividing blasts.
Side effects: Low blood counts, infection, mucositis, nausea, conjunctivitis (use steroid eye drops with HiDAC), cerebellar toxicity at high doses (monitor finger-nose testing), liver enzyme rise.
2) Daunorubicin
Class: Anthracycline.
Dosage/time: “3” of “7+3”: 60–90 mg/m² IV push Days 1–3.
Purpose: Partner with cytarabine for induction.
Mechanism: Intercalates DNA, inhibits topoisomerase II, generates free radicals.
Side effects: Myelosuppression, nausea, mucositis, hair loss, cardiomyopathy risk (track cumulative dose, baseline and follow-up echocardiograms), red-orange urine discoloration.
3) Idarubicin
Class: Anthracycline.
Dosage: 12 mg/m² IV Days 1–3 as an alternative to daunorubicin.
Purpose: Induction in suitable patients.
Mechanism: Similar to daunorubicin with higher intracellular retention.
Side effects: As above (myelosuppression, mucositis, cardiotoxicity risk).
4) Mitoxantrone
Class: Anthracenedione (Topo II inhibitor).
Dosage: 12 mg/m² IV Days 1–3 in some salvage or consolidation regimens.
Purpose: An option when anthracyclines are less suitable.
Mechanism: DNA intercalation and topoisomerase II inhibition.
Side effects: Myelosuppression, mucositis, cardiotoxicity (monitor), blue-green urine tinge.
5) CPX-351 (liposomal daunorubicin + cytarabine)
Class: Fixed-ratio liposomal combo.
Dosage: Induction 44/100 mg/m² IV Days 1, 3, 5; consolidation Days 1, 3.
Purpose: For therapy-related AML or AML with myelodysplasia-related changes; improves outcomes in selected adults.
Mechanism: Delivers drugs at a synergistic 1:5 molar ratio to blasts.
Side effects: Prolonged neutropenia, infections, mucositis; anthracycline cardiac risks apply.
6) Azacitidine
Class: Hypomethylating agent (HMA).
Dosage: 75 mg/m² SC/IV Days 1–7 every 28 days; often with venetoclax in older/unfit AML.
Purpose: Lower-intensity frontline or maintenance in selected settings.
Mechanism: DNA hypomethylation reactivates silenced genes and promotes differentiation.
Side effects: Cytopenias, nausea, injection-site reactions, fatigue.
7) Decitabine
Class: HMA.
Dosage: 20 mg/m² IV Days 1–5 every 28 days (or 10-day schedules).
Purpose: Alternative to azacitidine; often with venetoclax.
Mechanism: Similar to azacitidine, demethylates DNA.
Side effects: Cytopenias, infections, GI upset.
8) Venetoclax
Class: BCL-2 inhibitor (targeted).
Dosage: Ramp-up to 400 mg PO daily; reduce dose with strong CYP3A inhibitors (e.g., azole antifungals). Often combined with an HMA or low-dose cytarabine.
Purpose: Frontline for older/unfit adults and in relapsed settings.
Mechanism: Promotes apoptosis by blocking BCL-2.
Side effects: Tumor lysis syndrome (TLS—need prophylaxis), cytopenias, nausea, diarrhea; strong drug-interaction profile (avoid grapefruit).
9) Midostaurin
Class: FLT3 multikinase inhibitor.
Dosage: 50 mg PO twice daily on Days 8–21 with 7+3 induction and with consolidation for FLT3-mutated AML; can be used as maintenance.
Purpose: Improves outcomes when FLT3 mutation present.
Mechanism: Inhibits FLT3 signaling, reducing blast proliferation.
Side effects: Nausea, rash, QT prolongation risk; avoid grapefruit/CYP3A inhibitors.
10) Gilteritinib
Class: FLT3 inhibitor (selective).
Dosage: 120 mg PO daily for relapsed/refractory FLT3-mutated AML.
Purpose: Single-agent targeted therapy in R/R disease.
Mechanism: Blocks FLT3-ITD and TKD signaling.
Side effects: Elevated liver enzymes, differentiation syndrome, QT prolongation.
11) Quizartinib
Class: FLT3-ITD inhibitor.
Dosage: Commonly 60 mg PO daily (confirm per current protocol); used in specific regions/indications.
Purpose: Targeted option for FLT3-ITD AML per local approvals.
Mechanism: Inhibits FLT3-ITD signaling.
Side effects: QT prolongation, cytopenias; ECG monitoring required.
12) Ivosidenib
Class: IDH1 inhibitor.
Dosage: 500 mg PO daily in IDH1-mutated AML (newly diagnosed unfit or R/R).
Purpose: Targeted therapy to induce differentiation.
Mechanism: Blocks mutant IDH1, lowers oncometabolite 2-HG, allows normal maturation.
Side effects: Differentiation syndrome (urgent steroids), QT prolongation, leukocytosis.
13) Enasidenib
Class: IDH2 inhibitor.
Dosage: 100 mg PO daily in IDH2-mutated R/R AML.
Purpose: Targeted therapy promoting differentiation.
Mechanism: Inhibits mutant IDH2 to reduce 2-HG.
Side effects: Differentiation syndrome, bilirubin rise without true injury, nausea.
14) Gemtuzumab ozogamicin (GO)
Class: Anti-CD33 antibody-drug conjugate (calicheamicin).
Dosage: 3 mg/m² (max 4.5 mg) IV on Days 1, 4, 7 in combination schedules; other single-dose strategies exist.
Purpose: For CD33-positive AML in selected patients; can improve event-free survival in favorable/intermediate risk.
Mechanism: Delivers toxin directly to CD33+ blasts.
Side effects: Myelosuppression, liver injury including sinusoidal obstruction syndrome (SOS), infusion reactions.
15) Glasdegib
Class: Hedgehog pathway inhibitor (SMO).
Dosage: 100 mg PO daily with low-dose cytarabine in older/unfit adults.
Purpose: Low-intensity combination option.
Mechanism: Inhibits Hedgehog signaling to target leukemic stem cells.
Side effects: Anemia, fatigue, dysgeusia, muscle spasms, QT prolongation.
(Important supportive drugs often used alongside the above include antimicrobials, antiemetics, allopurinol/rasburicase for TLS, and transfusions. Your team will individualize these.)
Dietary Molecular Supplements
Always ask your oncology team before starting any supplement. Some antioxidants and herbal products can reduce chemotherapy effectiveness or raise drug levels.
1) Vitamin D3
Dosage: Typical 1000–2000 IU/day; higher only if deficient and supervised.
Function: Bone, immune modulation, mood.
Mechanism: Nuclear receptor signaling supports bone turnover and may modulate innate immunity.
2) Omega-3 (EPA/DHA fish oil)
Dosage: 1 g/day combined EPA+DHA with meals (avoid high doses around procedures).
Function: Anti-inflammatory support and appetite aid in some patients.
Mechanism: Competes with arachidonic acid pathways; may improve triglycerides and cachexia symptoms.
3) Oral rehydration salts/electrolytes
Dosage: Small, frequent sips to meet care-team fluid goals.
Function: Prevent dehydration from fever, diarrhea, or poor intake.
Mechanism: Sodium-glucose co-transport improves fluid absorption.
4) Protein with leucine (whey or medical nutrition shake)
Dosage: 20–30 g protein per serving, 1–2 times/day if intake is low.
Function: Maintain muscle mass.
Mechanism: Leucine triggers mTOR-mediated protein synthesis.
5) L-glutamine (oral)
Dosage: Commonly 10 g 2–3 times/day short-term for mucositis if approved.
Function: May reduce mouth soreness; evidence varies by setting.
Mechanism: Fuel for enterocytes; supports mucosal repair.
6) Soluble fiber (psyllium) when counts permit
Dosage: 3–5 g/day with water; avoid if severe neutropenia and mucosal damage unless approved.
Function: Bowel regularity.
Mechanism: Increases stool water and short-chain fatty acid production.
7) Zinc (bisglycinate or gluconate)
Dosage: 8–11 mg elemental/day; short course for deficiency.
Function: Taste recovery, wound healing, immune enzymes.
Mechanism: Cofactor for many enzymes and transcription factors.
8) Selenium (low dose)
Dosage: 50–100 mcg/day if diet is poor; avoid high doses.
Function: Antioxidant enzyme cofactor (glutathione peroxidase).
Mechanism: Supports redox balance; avoid high-dose antioxidants during chemo.
9) Ginger (standardized)
Dosage: ~0.5–1 g/day in divided doses.
Function: Helps nausea in some patients.
Mechanism: Serotonin and cholinergic pathway modulation in the gut.
10) Vitamin B12 and folate only if deficient
Dosage: Per lab-guided replacement.
Function: Correct megaloblastic anemia from deficiency (not AML).
Mechanism: DNA synthesis cofactors; avoid unsupervised high doses.
Immunity-Booster / Regenerative / Stem-Cell-Related” Drugs
(These are supportive or transplant-related—not anti-leukemia chemotherapies themselves. Use only under oncology guidance.)
1) Filgrastim (G-CSF)
Dosage: 5 mcg/kg SC daily until neutrophil recovery, per protocol.
Function: Shorten neutropenia after chemo.
Mechanism: Stimulates neutrophil production.
Notes: Bone pain, rare spleen enlargement.
2) Pegfilgrastim (long-acting G-CSF)
Dosage: 6 mg SC once per cycle when appropriate.
Function: Similar to filgrastim with single dose.
Mechanism: Prolonged G-CSF activity.
Notes: Not always used during induction; follow center protocol.
3) Sargramostim (GM-CSF)
Dosage: 250 mcg/m²/day SC/IV.
Function: Broader myeloid recovery.
Mechanism: Stimulates granulocytes and macrophages.
Notes: Fever, bone pain, fluid retention.
4) IVIG (intravenous immunoglobulin)
Dosage: 0.4 g/kg/day for 3–5 days or 0.8–1 g/kg once, for selected hypogammaglobulinemia with recurrent infections.
Function: Passive immune support.
Mechanism: Provides pooled antibodies.
Notes: Headache, aseptic meningitis, thrombosis risk; screen for IgA deficiency.
5) Eltrombopag (TPO receptor agonist) select cases
Dosage: 50–75 mg PO daily; adjust for liver function.
Function: Raise platelets in certain prolonged thrombocytopenia scenarios.
Mechanism: Stimulates megakaryocytes via c-Mpl.
Notes: Not routine during AML induction; risk-benefit varies.
6) Plerixafor (mobilization in transplant settings)
Dosage: 0.24 mg/kg SC prior to collection (mainly for donors or certain autologous settings).
Function: Stem cell mobilization for collection.
Mechanism: CXCR4 antagonist releases stem cells to blood.
Notes: AML recipients more commonly undergo allogeneic transplant using donor cells; your center guides specifics.
Key Procedures/“Surgeries”
(These are procedures done for AML care; some are not classic surgeries, but they are vital.)
1) Allogeneic hematopoietic stem cell transplant (HSCT)
Procedure: High-dose chemo (± radiation), then infusion of donor stem cells; long hospital stay.
Why: Offers best chance of long-term control or cure in many intermediate/high-risk AML cases.
2) Leukapheresis for leukostasis
Procedure: Machine removes white cells from blood.
Why: Rapidly lowers very high blast counts causing breathing or brain symptoms while chemo starts.
3) Central venous catheter (port or PICC) placement
Procedure: Small operation to place line into large vein.
Why: Safe delivery of chemo, transfusions, and blood draws.
4) Lumbar puncture with intrathecal therapy (select cases)
Procedure: Needle places medicine into spinal fluid.
Why: Diagnose/treat CNS involvement or give prophylaxis in specific subtypes.
5) Fertility preservation procedures (before treatment when possible)
Procedure: Sperm banking, oocyte or embryo cryopreservation.
Why: Protect fertility from chemo effects.
Preventions and Safety Habits
-
Fever plan: Call immediately for temperature ≥38.3°C once or ≥38.0°C for an hour.
-
Hand hygiene: Wash or sanitize before meals, after bathroom, and after touching public surfaces.
-
Food safety: Well-cooked meats and eggs; avoid raw sushi, unpasteurized dairy, salad bars, and buffets during low counts.
-
Crowd and mask strategy: Use masks in clinics and crowded indoor spaces during neutropenia.
-
Oral care: Soft brush, bland rinses (salt/baking soda), avoid alcohol mouthwash; report mouth sores.
-
Bleeding precautions: Electric razor, soft toothbrush, avoid contact sports; check stools and urine for blood.
-
Drug-interaction awareness: Avoid grapefruit and Seville orange with many targeted pills; check all new meds or herbs.
-
Sun and skin care: Moisturize, protect from sun, report rashes or infections early.
-
Vaccination timing: Household members up to date with inactivated vaccines; patient vaccines planned by team (live vaccines usually avoided).
-
Smoke/benzene avoidance: Do not smoke; avoid solvent and benzene exposure.
When to See Doctors Urgently
-
Fever, chills, or feeling acutely unwell.
-
Bleeding that is new or hard to stop, black stools, or vomiting blood.
-
Shortness of breath, chest pain, new confusion, severe headache, vision change.
-
Rapidly worsening swelling, redness, or pain at any site.
-
Little or no urine, severe diarrhea, or signs of dehydration.
-
Painful mouth sores with inability to drink.
-
Any new severe side effect after starting a drug (especially rash with swelling, jaundice, or suspected differentiation syndrome: sudden fever, weight gain, breathing trouble while on IDH/FLT3 inhibitors—call immediately).
Foods: What to Eat and What to Avoid
Eat (as tolerated and approved by your team):
-
Well-cooked protein (chicken, fish, eggs cooked firm, legumes).
-
Cooked vegetables; peeled or thoroughly washed fruits.
-
Fortified grains, oatmeal, rice, pasta for energy.
-
Yogurt made from pasteurized milk if allowed; otherwise choose lactose-free or plant alternatives.
-
Small, frequent meals and oral nutrition drinks if appetite is low.
Avoid (especially during neutropenia):
- Raw or undercooked meats, eggs, seafood, and unpasteurized dairy.
- Salad bars, buffets, and foods sitting at room temperature.
- Unwashed fresh produce; sprouts.
- Alcohol excess; avoid completely if liver tests are high.
- Grapefruit, pomelo, and Seville orange products with drugs like venetoclax, midostaurin, gilteritinib, and many azoles.
Frequently Asked Questions
1) Can AML be cured?
Yes. Many people reach remission, and some are cured, especially with the right combination of chemo, targeted drugs, and sometimes transplant. Results depend on age, fitness, and leukemia genetics.
2) Why is treatment started quickly?
AML grows fast. Early treatment lowers life-threatening risks like infection, bleeding, and organ problems from high blast counts.
3) What tests guide treatment?
Bone marrow biopsy, cytogenetics (karyotype), FISH, and DNA sequencing find changes like FLT3, NPM1, IDH1/2 that guide targeted drugs and transplant plans.
4) What is “7+3”?
Seven days of cytarabine plus three days of an anthracycline (daunorubicin or idarubicin). It is a classic induction regimen for fit adults.
5) What is differentiation syndrome?
A sudden, dangerous inflammatory reaction that can happen with IDH or FLT3 inhibitors. Symptoms include fever, shortness of breath, weight gain, and fluid in lungs. It needs urgent steroids and medical care.
6) Will I lose my hair?
Many chemo drugs cause hair loss. It usually starts 2–3 weeks after treatment begins and grows back after therapy ends.
7) How are infections prevented?
Hand hygiene, safe food, masks in crowds, avoiding sick contacts, quick antibiotics for fever, and sometimes preventive meds.
8) Do I need a transplant?
Some people do, especially if genetics show higher relapse risk. Your team compares expected benefits and risks and checks donor options.
9) Can I work or exercise?
Light activity is healthy if your counts and symptoms allow. Many people reduce or pause work during induction and resume gradually during recovery.
10) What about fertility?
Chemo can harm fertility. Ask before treatment about sperm banking or egg/embryo freezing whenever time allows.
11) Are “natural” supplements safe?
Not always. Some herbs and antioxidants interact with chemo or targeted pills. Always check with your team first.
12) How is nausea controlled?
Modern anti-nausea drugs, meal timing, ginger, and hydration help. Tell your team early so they can adjust medicines.
13) What if I feel very tired?
Fatigue is common. Use pacing, short daily activity, good sleep habits, and nutrition; report severe fatigue for evaluation.
14) How often are transfusions needed?
During treatment many people need red cell or platelet transfusions. This is normal supportive care.
15) What happens after remission?
You usually get consolidation therapy (chemo ± targeted therapy). Some proceed to transplant based on risk; others continue maintenance or monitoring.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 07, 2025.
